Please assess the completion status of the following clinical trial:

Trial Title: Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* MDD with a HAM-D score of \> 21 and \> 1 on Item 1~Exclusion Criteria:~* Axis I disorder in last 6 months~* Axis II disorder causing significant impact~* Current depressive episode \> 12 months or \< 4 weeks~* No response of current episode to \> 6 weeks treatment with 2 or more classes of antidepressant medication~* Substance abuse or dependence in last 6 months~* Significant medical illness~* Conditions that may alter study drug metabolism~* Significant suicide or homicide risk~* HAM-D Item 3 score \> 2~* Suicide attempt in the last 6 months~* Lab or physical exam abnormalities~* CYP34A inhibitors in last 2 weeks~* Active psychotherapy (not supportive) unless ongoing for \> 3 months~* Antipsychotic, antidepressant, or mood stabilizer in last 7 days (28 days for fluoxetine), MAOI or anxiolytic in last 14 days, or deport antipsychotic within 2 dosing intervals.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Quetiapine XR 50mg (Type: EXPERIMENTAL): Quetiapine XR 50mg OD for 6 weeks
- Placebo 1 (Type: PLACEBO_COMPARATOR): Placebo OD for 6 weeks
- Quetiapine XR 150-300mg (Type: EXPERIMENTAL): Quetiapine XR 150-300mg OD for 6 weeks
- Placebo 2 (Type: PLACEBO_COMPARATOR): Placebo OD for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).